Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Change in Account Payables (2016 - 2019)

Historic Change in Account Payables for Ultragenyx Pharmaceutical (RARE) over the last 4 years, with Q3 2019 value amounting to $3.9 million.

  • Ultragenyx Pharmaceutical's Change in Account Payables rose 29857.8% to $3.9 million in Q3 2019 from the same period last year, while for Sep 2019 it was $4.2 million, marking a year-over-year increase of 51767.03%. This contributed to the annual value of $3.4 million for FY2018, which is 251.52% down from last year.
  • Latest data reveals that Ultragenyx Pharmaceutical reported Change in Account Payables of $3.9 million as of Q3 2019, which was up 29857.8% from -$3.5 million recorded in Q2 2019.
  • Ultragenyx Pharmaceutical's 5-year Change in Account Payables high stood at $4.0 million for Q4 2018, and its period low was -$3.5 million during Q2 2019.
  • Over the past 4 years, Ultragenyx Pharmaceutical's median Change in Account Payables value was $187000.0 (recorded in 2016), while the average stood at $639933.3.
  • Examining YoY changes over the last 5 years, Ultragenyx Pharmaceutical's Change in Account Payables showed a top increase of 169893.05% in 2017 and a maximum decrease of 34326.45% in 2017.
  • Ultragenyx Pharmaceutical's Change in Account Payables (Quarter) stood at -$1.3 million in 2016, then soared by 68.66% to -$420000.0 in 2017, then skyrocketed by 1044.05% to $4.0 million in 2018, then decreased by 1.39% to $3.9 million in 2019.
  • Its last three reported values are $3.9 million in Q3 2019, -$3.5 million for Q2 2019, and -$151000.0 during Q1 2019.